Scholar Rock Holding (SRRK) Restructuring Costs (2024 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Restructuring Costs of $16.1 million in Q1 2026, up 26.48% quarter-over-quarter from $12.8 million in Q4 2025, and up 80.41% on a YoY basis from $8.9 million in Q1 2025.
Scholar Rock Holding (SRRK) Restructuring Costs (2024 - 2026) Analysis & Trends
Scholar Rock Holding's Restructuring Costs history runs 3 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- In Q1 2026, Restructuring Costs rose 80.41% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $63.3 million (up 140.35% YoY), while the FY2025 annual figure was $56.1 million, up 150.55% from the prior year.
- Restructuring Costs was $16.1 million for Q1 2026 at Scholar Rock Holding, up from $12.8 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $19.4 million in Q3 2025 to a low of $5.0 million in Q1 2024.
- Historically, Restructuring Costs has averaged $10.5 million across 3 years, with a median of $8.9 million in 2025.
- Biggest YoY gain for Restructuring Costs was 281.56% in 2025; the steepest drop was 78.8% in 2025.
- A 3-year view of Restructuring Costs shows it stood at $6.2 million in 2024, then surged by 106.96% to $12.8 million in 2025, then grew by 26.48% to $16.1 million in 2026.
- The last three Restructuring Costs figures came in at $16.1 million (Q1 2026), $12.8 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.13 Mn |
| Dec 31, 2025 | 12.76 Mn |
| Sep 30, 2025 | 19.43 Mn |
| Jun 30, 2025 | 14.95 Mn |
| Mar 31, 2025 | 8.94 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Sep 30, 2024 | 5.09 Mn |
| Jun 30, 2024 | 6.13 Mn |
| Mar 31, 2024 | 5.00 Mn |